Evidence map›Paper›PMID 38938908›Full record

ArticleCureus2024

Multi-centre Study of Vaping Effects on COVID-19 Presentations in Western Sydney Australia.

Anne Lazari, Daniel Sada

Abstract read
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anne LazariMedicine, Oceania University of Medicine, Sydney, AUS.
Daniel SadaFamily Medicine, Greenway Medical Hub, Sydney, AUS.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim

methodExtracted data from questionnaires completed by 100 Australians residing in the Western Sydney region who were infected with COVID-19 during the pandemic from March 2020 to March 2022 were analyzed. Data collected included patient age, biological gender, years of vaping, if vaping began prior to COVID-19, weekly vaping frequency, the year that COVID-19 was contracted, and the category of COVID-19 symptoms. The symptoms are scaled into four categories for this study, from lowest severity to high severity based on the World Health Organization's classifications.

resultsVapers in Western Sydney Australia experienced higher severity COVID-19 presentations compared to non-vapers. Biological males were found to be more susceptible than biological females for experiencing the highest severity. Vapers with higher years of vaping had severe COVID-19 presentations compared to lesser years of vaping.

conclusionAmong adults in Western Sydney Australia aged 18 years and above, the collected data showed a correlation between e-cigarette vapers reporting higher severity of COVID-19 presentations compared to non-vapers of the same demographic when they contracted COVID-19.

Indexed as

covid-19effects of vapingelectronic cigarettes (e-cigarettes)vaping and covid-19vaping-related lung injury

Identifiers

PMID38938908
PMCPMC11210441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.